Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DNA X, Inc.SONM · Entity 8261 | Director | June 09, 2020 | June 11, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DNA X, Inc.
Report date June 09, 2020 · Filed June 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,000 |
Ending reported balance
After 2020-06-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-06-09 · Grant · Acquired 104,000 · Balance 119,000 F1: Represents the grant of restricted stock units that vest in four equal annual installments beginning on June 9, 2020. Row 2 · 2020-06-09 · Purchase · Acquired 15,000 · Balance 134,000 F2: Represents shares of Common Stock purchased directly from the underwriters in an underwritten public offering conducted by the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest in four equal annual installments beginning on June 9, 2020.
F2: Represents shares of Common Stock purchased directly from the underwriters in an underwritten public offering conducted by the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2020 Filed Jun 11, 2020 21:14 UTC | DNA X, Inc. SONM · Entity 8261 | PurchaseCommon Stock | 15,000 | $0.75 | $11,250.00 |
DisclosureSEC source: 0001209191-20-036001 · doc4.xml · nonDerivative · entry 2 Hochschild Maurice · CIK 0001775162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,000 F2 · shares: Represents shares of Common Stock purchased directly from the underwriters in an underwritten public offering conducted by the Issuer. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 21:14 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 104,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036001 · doc4.xml · nonDerivative · entry 1 Hochschild Maurice · CIK 0001775162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,000 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning on June 9, 2020. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 23:12 UTC | DNA X, Inc. SONM · Entity 8261 | GrantStock Option (right to buy) · Derivative | 43,928 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001209191-20-000419 · doc4.xml · derivative · entry 1 Hochschild Maurice · CIK 0001775162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,928 Underlying: Common Stock · 43,928 shares Expires 2029-12-29 F1 · derivative.exercise_date: The Options shall vest: (a) with respect to 75% of the shares at such time as the price of the Company's Common Stock equals or exceeds $5.00 per share, (b) with respect to 15% of the shares at such time as the price of the Company's Common Stock equals or exceeds $7.00 per share; and (c) with respect to 10% of the shares at such time as the price of the Company's Common Stock equals or exceeds $8.00 per share, provided that all shares shall vest in full upon consummation of a change in control transaction. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 23:34 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-056813 · doc4.xml · nonDerivative · entry 1 Hochschild Maurice · CIK 0001775162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents the grant of restricted stock units (the "RSU") that vest in three equal annual installments beginning on May 9, 2019, subject to continued service. The RSU is the initial equity grant to which each non-employee director is entitled for service on the Issuer's board of directors pursuant to the non-employee director compensation policy that has been approved by the compensation committee of the Issuer's board of directors. The number of shares subject to the RSU was determined by reference to the price of the Issuer's common stock in its initial public offering, or $11 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.